SB
LXRX icon

Suntrust Banks’s Lexicon Pharmaceuticals LXRX Stock Holding History

Suntrust Banks’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,794
Closed -$33K – 1567
2014
Q1 		$33K Hold
2,794
– – ﹤0.01% 1888
2013
Q4 		$35K Hold
2,794
– – ﹤0.01% 1820
2013
Q3 		$46K Buy
2,794
+164
+6% +$2.75K ﹤0.01% 1793
2013
Q2 		$39K Buy
+2,630
New +$40K ﹤0.01% 1692

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Suntrust Banks's LXRX Position: Q2 2014 in Review

Suntrust Banks sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2014, closing a stake of 2,794 shares — an estimated $33K sold.

Suntrust Banks first reported a position in LXRX in Q2 2013 and held it in 4 quarters. The position peaked at $46K in Q3 2013. 99 funds tracked by Wall St. Rank hold LXRX as of Q2 2014.

  • Suntrust Banks reported no remaining Lexicon Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Suntrust Banks sold 2,794 Lexicon Pharmaceuticals shares in Q2 2014, an estimated $33K.
  • Suntrust Banks first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Suntrust Banks's Lexicon Pharmaceuticals position peaked at $46K in Q3 2013.
  • 99 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2014.

Based on Suntrust Banks's 13F filing for Q2 2014, filed 14 Aug 2014.